ABATACEPT (a-ba-ta ' sept) Orencia Classifications: biologic response modifier; fusion protein; disease-modifying antirheumatic drug (dmard); Therapeutic:antirheumatic (dmard); antiinflammatory Pregnancy Category: C |
250 mg lyophilized powder for injection
Abatacept inhibits T-cell (T lymphocyte) proliferation and inhibits production of tumor necrosis factor (TNF)-alpha, interferon-gamma, and interleukin-2. It suppresses inflammation, decreases anticollagen antibody production, and reduces antigen-specific production of interferon-gamma.
Abatacept is used to reduce the number of activated T lymphocytes found in synovial fluid of rheumatoid arthritis patients. It relieves symptoms of rheumatoid arthritis and slows progression of structural damage. It improves physical function in adults with active rheumatoid arthritis who have had an inadequate response to other drugs.
Treatment of moderate to severe rheumatoid arthritis in patients with an inadequate response to one or more disease-modifying antirheumatic drugs (DMARDs). It may be used as monotherapy or in combination with other DMARDs, with the exception of TNF antagonists.
Known hypersensitivity to abatacept; live vaccines; active infections; co-administration with anakinra; pregnancy (category C); lactation.
COPD, RA; malignancies.
Rheumatoid Arthritis Adult: IV <60 kg, 500 mg; 60100 kg, 750 mg; >100 kg, 1000 mg q2wk x 2, then q mo |
Intravenous PREPARE: IV Infusion: Use the supplied silicone-free disposable syringe with an 1821 gauge needle to reconstitute the vial. Add 10 mL sterile water to yield 25 mg/mL. To avoid foaming, gently swirl until completely dissolved. Do not shake or vigorously agitate. After dissolving, vent the vial with a needle to dissipate any foam. The reconstituted solution must be further diluted to a total of 100 mL as follows: from a 100 mL NS IV bag remove a volume equal to the total volume of abatacept in the reconstituted vials (e.g., for 2 vials, remove 20 mL). Using the supplied silicone-free syringe, slowly add the reconstituted abatacept to the IV bag and gently mix. The final concentration of the IV solution will be approximately 5, 7.5, or 10 mg/mL, depending on whether 2, 3, or 4 vials are used. Discard any unused abatacept. ADMINISTER: IV Infusion: Use a 0.21.2 micron low-protein-binding filter. Infuse over 30 min. INCOMPATIBILITIES Solution/additive: Should not be infused in the same intravenous line with other agents. Y-site: Should not be infused in the same intravenous line with other agents. |
Assessment & Drug Effects
Patient & Family Education